Hematopoietic stem cell transplantation: a primer for the primary care physician
- Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Kulkarni, S; Rodriguez, M; Lafuente, A; Mateos, P; Mehta, J; Singhal, S; Saso, R; Tait, D; Treleaven, J G; Powles, R L // Bone Marrow Transplantation;4/15/99, Vol. 23 Issue 8, p803
Seventeen patients who developed hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation were treated with recombinant tissue plasminogen activator (rtPA) with or without heparin. rtPA was started a median of 13 days post transplant (range 4â€“35). All...
- Haematopoietic stem cell transplantation for thalassaemia major in Hong Kong: prognostic factors and outcome. Li, C. K.; Shing, M. M. K.; Chik, K. W.; Lee, V.; Leung, T. F.; Cheung, A. Y. K.; Yuen, M. P. // Bone Marrow Transplantation;1/15/2002, Vol. 29 Issue 2, p101
Deals with a study which analyzed the factors affecting the outcome of thalassaemia major patients after hematopoietic stem cell transplantation. Patients and methods; Results; Discussion.
- Antiviral agent reduced cytomegalovirus disease after HSCT. // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p46
The article presents the results of a randomized study as of late October 2013, which showed that patients who underwent hematopoietic stem cell transplantation were less likely to contract cytomegalovirus diseases when treated with higher doses of the antiviral agent brincidofovir.
- Allogeneic HSCT improved outcomes for children with relapsed ALL. // Hem/Onc Today;8/10/2013, Vol. 14 Issue 15, p20
The article discusses research in Germany on the benefit of allogeneic hematopoietic stem cell transplantation (HSCT) in improving the prognosis of patients with acute lymphoblastic leukemia (ALL), referencing a study by C. Eckert published in an issue of the "Journal of Clinical Oncology."
- Regionally limited or rare infections: prevention after hematopoietic cell transplantation. Gea-Banacloche, J; Masur, H; da Cunha, C Arns; Chiller, T; Kirchhoff, L V; Shaw, P; Tomblyn, M; Cordonnier, C // Bone Marrow Transplantation;Apr2010, Vol. 45 Issue 4, p806
A correction to the article "Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective" that was published in 2009 issue is presented.
- Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Bush, N.; Donaldson, G.; Moinpour, C.; Haberman, M.; Milliken, D.; Markle, V.; Lauson, J. // Quality of Life Research;Feb2005, Vol. 14 Issue 1, p77
We believe that many adverse events following hematopoietic stem cell transplantation (HSCT), particularly relapse and chronic graft-versus-host disease (CGVHD), are preceded by a subclinical period of development that is accessible by frequent psychometric assessment. Documenting these...
- Hospital Infection Control in Hematopoietic Stem Cell Transplant Recipients. Dykewicz, Clare A. // Emerging Infectious Diseases;Mar/Apr2001, Vol. 7 Issue 2, p263
Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients contains a section on hospital infection control including evidence-based recommendations regarding ventilation, construction, equipment, plants, play areas and toys, health-care workers,...
- Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms. Sebastián, E.; Martín, J.; McDonald, G. B.; Flores, T.; Rodríguez, A.; Blanco, A.; Vazquez, L.; de Fuentes, I.; Caballero, M. D. // Bone Marrow Transplantation;Apr2011, Vol. 46 Issue 4, p612
A letter to the editor is presented concerning a 46-year-old follicular lymphoma patient who was diagnosed to have cryptosporidium parvum infection and graft versus host diseases (GVHD) after undergoing allogeneic hematopoietic stem cell transplantation (SCT).
- Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. Moore, J; Englert, H; Furlong, T; Poon, T; Milliken, S; Ma, D // Bone Marrow Transplantation;Nov2012, Vol. 47 Issue 11, p1486
A letter to the editor is presented which discusses the haematopoietic stem cell transplantation (HSCT) responses in patients with severe systemic sclerosis (Ssc).